Autopsy report · NCT05241873
(Concerto) Study of BLU-451 in Advanced Cancers With EGFR Exon 20 Insertion Mutations
Cause of deathFunding or business
“Sponsor decision, not related to safety concerns”
Life of this trial
- Registered 1 month before it started.
- Ran for about 2 years 5 months before it stopped.
- 103 participants enrolled.
- No results are posted on the registry.
Vital statistics
- Status
- Terminated
- Phase
- Phase 1
- Sponsor
- Blueprint Medicines Corporation
- Sponsor type
- Industry
- Conditions
- Lung Neoplasm Malignant; Carcinoma, Non-Small-Cell Lung; Respiratory Tract Neoplasms; Neoplasms; Neoplasms by Site; Lung Diseases
- Interventions
- BLU-451; Carboplatin; Pemetrexed
- Participants
- 103
- Sites
- 23
- Countries
- Canada, Japan, South Korea, Taiwan, United States
Trials that died the same way
- Effect of Lixisenatide on Postprandial Lipid Profile in Obese Type 2 Diabetic Patients
“Sponsor decision not related to safety reasons” - A Evaluation of 3D Functional MIRA System in Women With Mammographically Dense Breasts
“Sponsor decision, not safety related” - Study of SNX281 in Subjects With Advanced Solid Tumors and Lymphoma
“Sponsor decision (not due to safety concerns)” - NT-I7 in Combination With Atezolizumab in Previously Untreated, PD-L1-expressing, Locally Advanced or Metastatic NSCLC
“sponsor decision (not for safety)” - Double-blind, Randomized, Placebo-controlled Study Evaluating Efficacy and Safety of IgPro20 in Post-COVID-19 POTS
“Sponsor decision, not for safety reasons.”
Look deeper
- The official registry record (the source of truth)
- Record history: every change the sponsor made
- Open it in the database
Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.